Cardiogenesis Names Lee S. Langford Vice President, General Manager of Central Area
Tuesday February 8, 7:30 am ET
Accomplished Sales Leader Taking Helm of Expansion Division
FOOTHILL RANCH, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (OTC Bulletin Board: CGCP - News), the international market leader in surgical products and accessories used in angina-relieving Transmyocardial Revascularization (TMR) and Percutaneous Myocardial Channeling (PMC) procedures, announced today that Lee S. Langford, 31, an accomplished medical device sales professional and manager, has joined the Company as Vice President, General Manager of the Company's expansion Central Area, effective immediately. He will report directly to Chairman and CEO Michael J. Quinn.
ADVERTISEMENT
Prior to joining Cardiogenesis, Langford, from 2002-04 worked for Given Imaging, first as a Capital Sales Representative, then as a Regional Manager. Prior to that, from 2000-02 he excelled as a sales representative with Imagyn Medical Technologies in their surgical and oncology divisions. Langford is a graduate of the U.S. Military Academy (West Point) and served as a commissioned officer in the U.S. Army (Ranger Infantry Officer), attaining the rank of Captain.
Michael J. Quinn, Chairman and CEO stated, "Lee is an impressive sales professional and manager. Our senior management has direct experience in working with Lee in previous medical device companies, and has proactively recruited him to this important general management position. Lee joins our Company at an exciting time, with the roll out of the TMR PLUS advanced platform, including the celleratOR platelet rich plasma preparation (PRP). These initiatives received significant attention and interest at the recent Society of Thoracic Surgeons Meeting in Tampa."
Quinn also commented on the decision to add a fifth business unit to the organizational structure at this time. "The effective expansion of our U.S. salesforce is a critical component of our growth strategy for 2005. Lee possesses both the selling and leadership skills to immediately contribute to and help lead the effective expansion of the sales team. The addition of Lee to the management team at this time is important to us in ensuring our achievement of aggressive operating goals in 2005 and going forward."
Langford will immediately assume all operating responsibilities related to the Central Area of the U.S. sales organization.
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The Company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the Company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.
For more information on the Company and its products, please visit the Cardiogenesis company web site at www.cardiogenesis.com. Or the patient and physician website at www.heartofnewlife.com. heartofnewlife.com is a resource for patients and physicians which provides medical information on TMR.
With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the Company's sales, profitability, the adoption of its technology and products and FDA clearances are based on current expectations and beliefs and are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR or PMC procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2003, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004, and the Company's other recent SEC filings. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Contact: Cardiogenesis Corporation
Michael Quinn, Chairman & Chief Executive Officer, 714-649-5000
--------------------------------------------------------------------------------
Source: Cardiogenesis Corporation
